Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904)

Angel L. Guerrero-Zotano; Thomas P. Stricker; Luigi Formisano; Katherine E. Hutchinson; Daniel G. Stover; Kyung Min Lee; Luis J. Schwarz; Jennifer M. Giltnane; Monica V. Estrada; Valerie M. Jansen; Alberto Servetto; Joaquín J. Gavila; Alejandro Perez-Fidalgo; Ana Lluch; Antonio Llombart-Cussac; Mohamed Amine Bayar; Stefan Michiels; Fabrice Andre; Monica Arnedos; Vicente Guillem; Amparo Ruiz-Simon; Carlos L. Arteaga

doi:10.1158/1078-0432.CCR-18-4270

Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904)

Angel L. Guerrero-Zotano, Thomas P. Stricker, Luigi Formisano, Katherine E. Hutchinson, Daniel G. Stover, Kyung Min Lee, Luis J. Schwarz, Jennifer M. Giltnane, Monica V. Estrada, Valerie M. Jansen, Alberto Servetto, Joaquín J. Gavila, Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llombart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice Andre, Monica Arnedos, Vicente GuillemAmparo Ruiz-Simon, Carlos L. Arteaga

Résultats de recherche: Contribution à un journal › !!Comment/debate

1 Citation (Scopus)

Résumé

In the original version of this article (1), the stated disclosure of the author Carlos L. Arteaga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

langue originale	Anglais
Pages (de - à)	1431
Nombre de pages	1
journal	Clinical Cancer Research
Volume	25
Numéro de publication	4
Les DOIs	https://doi.org/10.1158/1078-0432.CCR-18-4270
état	Publié - 15 févr. 2019

Accès au document

10.1158/1078-0432.CCR-18-4270

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Guerrero-Zotano, A. L., Stricker, T. P., Formisano, L., Hutchinson, K. E., Stover, D. G., Lee, K. M., Schwarz, L. J., Giltnane, J. M., Estrada, M. V., Jansen, V. M., Servetto, A., Gavila, J. J., Perez-Fidalgo, A., Lluch, A., Llombart-Cussac, A., Bayar, M. A., Michiels, S., Andre, F., Arnedos, M., ... Arteaga, C. L. (2019). Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904). Clinical Cancer Research, 25(4), 1431. https://doi.org/10.1158/1078-0432.CCR-18-4270

Guerrero-Zotano, Angel L. ; Stricker, Thomas P. ; Formisano, Luigi et al. / Correction : ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904). Dans: Clinical Cancer Research. 2019 ; Vol 25, Numéro 4. p. 1431.

@article{00fb453301ee49409b34843b058e679e,

title = "Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904)",

abstract = "In the original version of this article (1), the stated disclosure of the author Carlos L. Arteaga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.",

author = "Guerrero-Zotano, {Angel L.} and Stricker, {Thomas P.} and Luigi Formisano and Hutchinson, {Katherine E.} and Stover, {Daniel G.} and Lee, {Kyung Min} and Schwarz, {Luis J.} and Giltnane, {Jennifer M.} and Estrada, {Monica V.} and Jansen, {Valerie M.} and Alberto Servetto and Gavila, {Joaqu{\'i}n J.} and Alejandro Perez-Fidalgo and Ana Lluch and Antonio Llombart-Cussac and Bayar, {Mohamed Amine} and Stefan Michiels and Fabrice Andre and Monica Arnedos and Vicente Guillem and Amparo Ruiz-Simon and Arteaga, {Carlos L.}",

note = "Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",

year = "2019",

month = feb,

day = "15",

doi = "10.1158/1078-0432.CCR-18-4270",

language = "English",

volume = "25",

pages = "1431",

journal = "Clinical Cancer Research",

issn = "1078-0432",

number = "4",

}

Guerrero-Zotano, AL, Stricker, TP, Formisano, L, Hutchinson, KE, Stover, DG, Lee, KM, Schwarz, LJ, Giltnane, JM, Estrada, MV, Jansen, VM, Servetto, A, Gavila, JJ, Perez-Fidalgo, A, Lluch, A, Llombart-Cussac, A, Bayar, MA, Michiels, S, Andre, F, Arnedos, M, Guillem, V, Ruiz-Simon, A & Arteaga, CL 2019, 'Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904)', Clinical Cancer Research, VOL. 25, Numéro 4, p. 1431. https://doi.org/10.1158/1078-0432.CCR-18-4270

Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904). / Guerrero-Zotano, Angel L.; Stricker, Thomas P.; Formisano, Luigi et al.
Dans: Clinical Cancer Research, Vol 25, Numéro 4, 15.02.2019, p. 1431.

Résultats de recherche: Contribution à un journal › !!Comment/debate

TY - JOUR

T1 - Correction

T2 - ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904)

AU - Guerrero-Zotano, Angel L.

AU - Stricker, Thomas P.

AU - Formisano, Luigi

AU - Hutchinson, Katherine E.

AU - Stover, Daniel G.

AU - Lee, Kyung Min

AU - Schwarz, Luis J.

AU - Giltnane, Jennifer M.

AU - Estrada, Monica V.

AU - Jansen, Valerie M.

AU - Servetto, Alberto

AU - Gavila, Joaquín J.

AU - Perez-Fidalgo, Alejandro

AU - Lluch, Ana

AU - Llombart-Cussac, Antonio

AU - Bayar, Mohamed Amine

AU - Michiels, Stefan

AU - Andre, Fabrice

AU - Arnedos, Monica

AU - Guillem, Vicente

AU - Ruiz-Simon, Amparo

AU - Arteaga, Carlos L.

PY - 2019/2/15

Y1 - 2019/2/15

N2 - In the original version of this article (1), the stated disclosure of the author Carlos L. Arteaga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

AB - In the original version of this article (1), the stated disclosure of the author Carlos L. Arteaga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

UR - http://www.scopus.com/inward/record.url?scp=85061570035&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-4270

DO - 10.1158/1078-0432.CCR-18-4270

M3 - Comment/debate

C2 - 30770490

AN - SCOPUS:85061570035

SN - 1078-0432

VL - 25

SP - 1431

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 4

ER -

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM et al. Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904). Clinical Cancer Research. 2019 févr. 15;25(4):1431. doi: 10.1158/1078-0432.CCR-18-4270